Evidence map›Paper›PMID 8563978›Full record

ArticleThe European journal of neuroscience1995

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites.

R Göke, P J Larsen, J D Mikkelsen, S P Sheikh

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in The European journal of neuroscience, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072963 (Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow), which is not on this map. Cited by 183 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
PMID 36871874PMID 29687620PMID 17848936PMID 33831607PMID 33585983PMID 33461618PMID 33222922PMID 33044181PMID 32982937PMID 32716707PMID 32588967PMID 32568367other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 2 syntheses or guidelines pooled it, 468 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Exposure-response analyses of liraglutide 3.0 mg for weight management.Diabetes, obesity & metabolism · 2016 · on this map
    Trial
  5. Trial
  6. Trial
  7. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.The Journal of clinical investigation · 1998 · on this map
    Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

R GökeDepartment of Clinical Biochemistry, Rigshospitalet 7642, University of Copenhagen, Denmark.
P J Larsen
J D Mikkelsen
S P Sheikh
University of Copenhagen · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The distribution and biochemical properties of glucagon-like peptide (GLP)-1(7-36) amide (GLP-1) binding sites in the rat brain were investigated. By receptor autoradiography of tissue sections, the highest densities of [125I]GLP-1 binding sites were identified in the lateral septum, the subfornical organ (SFO), the thalamus, the hypothalamus, the interpenduncular nucleus, the posterodorsal tegmental nucleus, the area postrema (AP), the inferior olive and the nucleus of the solitary tract (NTS). Binding studies with [125I][Tyr39] exendin-4, a GLP-1 receptor agonist, showed an identical distribution pattern of binding sites. Binding specificity and affinity was investigated using sections of the brainstem containing the NTS. Binding of [125I]GLP-1 to the NTS was inhibited concentration-dependently by unlabelled GLP-1 and [Tyr39]exendin-4 with KI values of 3.5 and 9.4 nM respectively. Cross-linking of hypothalamic membranes with [125I]GLP-1 or [125I][Tyr39]exendin-4 identified a single ligand-binding protein complex with a molecular mass of 63,000 Da. The fact that no GLP-1 binding sites were detected in the cortex but that they were detected in the phylogenetically oldest parts of the brain emphasizes that GLP-1 may be involved in the regulation of vital functions. In conclusion, the biochemical data support the idea that the central GLP-1 receptor resembles the peripheral GLP-1 receptor. Furthermore, the presence of GLP-1 binding sites in the circumventricular organs suggests that these may be receptors which act as the target for both peripheral blood-borne GLP-1 and GLP-1 in the nervous system.

Indexed as

VenomsAnimalsAutoradiographyBinding SitesBrainExenatideGlucagonGlucagon-Like Peptide 1Glucagon-Like PeptidesKineticsMalePeptide FragmentsPeptidesRadioligand AssayRatsRats, WistarExenatideGlucagonGlucagon-Like Peptide 1glucagon-like peptide 1 (7-36)amideGlucagon-Like PeptidesPeptide FragmentsPeptidesVenoms

Identifiers

PMID8563978
OpenAlexW1998882505

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.